Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 90,986 shares at $75.24 ($6.8M) on 2025-12-15, disclosed to the SEC on 2025-12-16.
Scheduled sale ($6.8M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $75.15 | 30,964 | $2.3M | 34.2% |
| 2 | $74.60 | 28,311 | $2.1M | 31.0% |
| 3 | $74.60 | 28,311 | $2.1M | 31.0% |
| 4 | $75.24 | 1,700 | $128K | 1.9% |
| 5 | $75.24 | 1,700 | $128K | 1.9% |
| Total | $74.81 avg | 90,986 |
| $6.8M |
| 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |